SFMI, LSTG, AMBS, PCFGD, SNDY, PDMI
Our Stocks to Watch today include Silver Falcon Mining Inc. (OTCBB: SFMI), Lone Star Gold Inc. (OTCBB: LSTG), Amarantus BioSciences (OTCBB: AMBS), Pacific Gold Corp. (OTCBB: PCFGD), Solos Endoscopy Inc. (OTC: SNDY) and Paradigm Medical Industries Inc. (OTCBB: PDMI).
SILVER FALCON MINING INCORPORATED (OTC: SFMI)
"Up 5.50% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SFMI.php
Silver Falcon Mining, Inc., is an exploration and development Company specializing in high-grade Gold and Silver mining properties in North America. For further information, visit www.silverfalconmining.com.
January 11 - Silver Falcon Mining, Inc. Provides Bullish Outlook on Its 2013 Mining Operations
Silver Falcon Mining, Inc. (OTCBB: SFMI) reports on its mining and milling operations, as management remains bullish on anticipated 2013 activities.
Diamond Creek Mill
The Company's Diamond Creek Mill's designed gravity feed circuit has been temporarily shut-down for its yearly heavy maintenance and component recalibrations. At the same time, the integration of the new floatation cell circuit is being added as a new component to the existing mill circuitry. Early testing of tailings material, from the floatation cells, reveals a significant improvement in recovery values of ALL precious metals. Management feels that once the flotation circuit is fully operational in the ensuing weeks, this will greatly improve bottom-line for the 2013 operational year.
The "Conditional Use" application for full implementation of the permitted closed-loop leaching system remains on-going and on scheduled without delays.
Further, management reports that work on the permanent storage of mill tailings will begin in earnest.
Diamond Creek Metallurgical Lab
The Company's metallurgical laboratory building which contains, the Bullion Dore facility, the lab facility and the secured vault, has been fully erected. Company workers are finishing the remaining interior architectural components, allowing this facility to be fully operational.
Sinker Tunnel Gold Project
The Company has been working within the Sinker Tunnel Gold Project as per directives approved by SFMI's Board of Directors. Due to mining rules, only SFMI personnel will be allowed inside the fenced in parameter of the project. As drilling, bolting, shoring, and exploration proceeds over the upcoming months, management will report as necessary on these operational developments.
Management remains excited about the fact that these are the first mining activities on War Eagle Mountain in over a century.
Pierre Quilliam, CEO, states, "After two years of efforts, both at the mill site and at the Sinker, it is very gratifying to see our efforts maturing. From a barren 20-acre site, the Diamond Creek Mill Facility has risen into an agglomeration of infrastructures, buildings, and equipment. The Company has one objective, to extract and deliver as much precious metals to the world markets as we can produce profitably from our holdings." He further mentions, "This is the year where production will become the mainstay of SFMI's objectives and operational motives. This in turn should deliver significant revenue to the Company and growth of shareholder values."
LONE STAR GOLD INCORPORATED (OTCBB: LSTG)
"Up 13.21% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/LSTG.php
Lone Star Gold, Inc. is a publicly-traded gold exploration and development company based in Albuquerque, New Mexico. The Company's aggressive acquisition and exploration approach is strategically focused on proven, stable precious metal regions in America and Mexico. Currently, Lone Star has a 70% Working Interest in concessions covering 800 hectares in the La Candelaria project in Chihuahua, Mexico, which the Company is evaluating to determine the potential sites that represent the best potential for silver and gold deposits. Lone Star also has an option to purchase a 70% interest in the Ocampo Project, a 570-hectare gold-silver project in Chihuahua State, Mexico, and an option to purchase an undivided 65% interest in the San Antonio del Potrero mine tailings project in the city of Hidalgo Del Parral in the state of Chihuahua, Mexico.
January 7 - Lone Star Gold, Inc. Announces $15M Investment Agreement Now Effective and Plans to Commence On-Site Processing Plant Construction
Lone Star Gold, Inc. (OTCBB: LSTG) ("Lone Star" or "the Company") announces the effectiveness of its Form S-1 dated December 20, 2012, which outlines the details of the Company's $15 million common-stock-purchase investment agreement with Deer Valley Management, LLC (see more details about the "Deer Valley Investment Agreement" further below).
Lone Star intends to raise capital through the Deer Valley Investment Agreement commencing January 2013. In particular, the Company will commence construction as soon as possible on its own on-site processing plant at its Tailings Project near the city of Hidalgo Del Parral in the state of Chihuahua, Mexico. The processing plant will further enhance Lone Star's ability to maximize the silver and gold content per ton of shipment from the project's 1.2 million tons of mine tailings. The plant will use the relatively new benign nitrogen leaching pile process. In Q3 2012, the Company's team in Mexico completed a preliminary leach plant development plan, which includes a processing capacity of 1,000 tons per day (tpd) while avoiding the use of cyanide and having minimal environmental impact. Leach testing has also been completed, which determined that no additional crushing of the tailings material is required and that expected recovery will be between the 88-90% range.
The Company expects the on-site processing plant to be operational within 3-4 months following access to the necessary funding through the Deer Valley Investment Agreement.
Lone Star's President, Daniel Ferris, commented: "We want to thank Deer Valley in bringing the $15 million Deer Valley Investment Agreement. We are now looking forward to a very active first few months of 2013 culminating in concentrate sales possibly commencing in April 2013."
DEER VALLEY INVESTMENT AGREEMENT DETAILS
By way of background, on April 30, 2012, Lone Star entered into an investment agreement with Fairhills Capital Offshore Ltd. ("Fairhills"). Under the agreement, Fairhills committed to purchase up to $15,000,000 of Lone Star's common stock over a period of up to 36 months. From time to time during the 36 months period, Lone Star may deliver a put notice to Fairhills, stating the dollar amount it intends to sell to Fairhills on a date specified in the put notice.
On November 12, 2012, Fairhills entered into an assignment and assumption agreement with Deer Valley Management, LLC ("Deer Valley"), pursuant to which Fairhills transferred and assigned all rights and obligations under the investment agreement to Deer Valley (the "Deer Valley Investment Agreement"). Fairhills and Deer Valley have common ownership and management. As outlined in Lone Star's Form S-1 filing, the Company may raise capital through the Deer Valley Investment Agreement as needed for current running costs, general operating expenses and capital expenditures related to Lone Star's Tailings Property and Candelaria Project, and, in particular, the construction of the nitrogen leach plant on Lone Star's Tailings Property. Further details of the Deer Valley Investment Agreement are available in Lone Star's Form S-1 filing from December 20, 2012.
AMARANTUS BIOSCIENCES INCORPORATED (OTCBB: AMBS)
"Up 7.69% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AMBS.php
Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson’s disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF").
January 22 - BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
* Approximately 468 Million Shares Shorted Since June 2011
* Short Squeeze Continues As Stock Above $0.06 SqueezeTrigger Price
BUYINS.NET, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on Amarantus BioSciences (AMBS) after releasing the latest short sale data through January 18, 2013. The total aggregate number of shares shorted since June 2011 is approximately 468 million shares. Approximately 29.28% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.06. A short squeeze has begun as stock is above its SqueezeTrigger Price.
Original Report: http://www.buyins.com/reports/ambs11-2-12.pdf
Updated SqueezeTrigger: http://www.buyins.com/images2/ambsstr1-21-13.jpg
Updated Friction Factor: http://www.buyins.com/images2/ambsff1-21-13.jpg
Brochure explaining data: http://www.buyins.com/brochure.pdf
Friction Factor calculates if a fair market is being made in the shares of AMBS. 59% of the previous 29 trading days have been positive or bullish-biased and 41% have been negative or bearish-biased.
PACIFIC GOLD CORPORATION (OTCBB: PCFGD)
"Up 50.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/PCFGD.php
Pacific Gold Corp. engages in the identification, acquisition, exploration, and development of mining prospects primarily in the United States. The company, through its subsidiaries, owns claims, property, and leases in Nevada, Oregon, and Colorado. Its property portfolio comprises 68 placer and lode mining claims, including the Black Rock Canyon Mine covering approximately 1,340 acres; 13.67 acres of land; and approximately 440 acres of leased land in Lander County, Nevada. Pacific Gold also owns 16 placer claims covering approximately 320 acres in Josephine County, Oregon, which include the Bear Bench project and Defiance Mine. In addition, the company owns 36 claims covering 640 acres of the Lower Olinghouse Placers, known as Butcher Boy and Teddy located 34 miles east of Reno, Nevada. Further, it has rights to claims within Project W, a tungsten project covering approximately 600 acres in Mineral County, Nevada, as well as owns 24 unpatented lode mining claims in San Juan and Dolores Counties, Colorado. The company was incorporated as Demand Financial International, Ltd. in 1996 and changed its name to Blue Fish Entertainment, Inc. in 2002. Further, it changed its name to Pacific Gold Corp. in 2003. The company is based in Reno, Nevada.
January 18 - Pacific Gold Corp.: Reverse Stock Split and Amended Articles of Incorporation
Pacific Gold Corp. (OTCBB: PCFGD) (the "Company") announced that, effective upon market open on January 22, 2013, every twenty shares of the Company''s issued and outstanding Common Stock, par value $0.0000000001 (the "Common Stock"), will convert into one share of Common Stock (the "Reverse Stock Split"). Any fractional shares resulting from the Reverse Stock Split will be rounded up to the next whole share. As a result of the Reverse Stock Split, the total number of issued and outstanding shares of the Company''s Common Stock will decrease from 3,867,674,530 pre-split shares to approximately 193,383,727 shares after giving effect to the Reverse Stock Split.
In addition, as part of the Reverse Stock Split, the Company will also be reducing its total number of authorized shares of common stock from 5,000,000,000 to 3,000,000,000 as approved by the Company''s stockholders at last year''s Annual Meeting.
At the open of business on January 22, 2013 the common stock of the Company will trade under the symbol PCFGD for a period of 20 business days after which time the D will be removed from the stock symbol.
SOLOS ENDOSCOPY INCORPORATED (OTC: SNDY)
"Up 15.38% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SNDY.php
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office.
January 16 - Solos Endoscopy Finishes 2012 Strong
Solos Endoscopy, Inc. (OTC: SNDY) announces that the Company experienced an approximate 16% increase in sales for the twelve months ended 2012 compared to 2011. Solos Endoscopy finished 2012 with $395,038.76 in sales, a 16% increase over 2011 sales of $340,626.22.
Solos Endoscopy's increase in sales for the twelve months ended 2012 can be attributed to a strong fourth quarter where the Company had three months of sales increases compared to the prior year. In October, Solos Endoscopy posted sales of $37,274.90; this represented an approximate 36% increase from the year prior sales of $27,455.52. In the month of November, sales increased by more than 53%; with sales of $27,818.96 for November 2011 compared to $42,631.56 for November 2012. In December 2012, Solos Endoscopy posted sales of $42,043.02 compared to $21,363.69 for the same period in 2011; this represented a 97% increase.
Solos management is pleased that it has been able to achieve these sales increases without any significant changes to its pricing or operations. In addition, management has previously announced that it has taken steps to increase the shelf life of its sterilized endoscopic instruments which should allow hospitals to order product in larger quantities. Solos Endoscopy posts its financial reports and disclosures according to OTC Market Guidelines. These disclosures can be viewed at http://www.otcmarkets.com/stock/SNDY/filings.
Solos Endoscopy instruments are FDA approved. The Company recently retained TUV SUD America, Inc. to complete its ISO 13485 Certification and Audit on its instruments including the MammoView®. The Company previously engaged Expert Resource to prepare the Company for the final audit. Expert Resource will attend the final audit, and help interpret any findings. According to Expert Resource, their consultants maintain a 100% success rate of passing the final audit on the first attempt.
PARADIGM MEDICAL INDUSTRIES INCORPORATED (OTCBB: PDMI)
"Up 100.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/PDMI.php
Paradigm Medical Industries, Inc. is a medical device company that develops, manufactures and distributes cutting edge, new innovative products in the diagnostic ultrasound and early glaucoma detection markets. Paradigm has the only patented technology utilizing photon laser for cataract removal. The Company is poised to capture a niche market within the Glaucoma and ultrasound microscopy fields. Paradigm Medical Industries markets its products to ophthalmologists, optometrists, universities, and clinics throughout the United States, as well as internationally.
No recent news for Paradigm Medical Industries, Inc. (OTCBB: PDMI).